INTRODUCTION
Patients with metastatic breast cancer are routinely exposed to anthracycline and taxane as neoadjuvant, adjuvant, and palliative chemotherapeutic agents. Although anthracycline and taxane are the most active first-line drugs for treating breast cancer, many patients will show disease progression and so they require further treatment with other chemotherapeutic agents. (1) Vinorelbine is a semisynthetic vinca alkaloid that has higher liposolubility and an increased tissue concentration than its analogues.(2) When utilized as a single agent against metastatic breast cancer, vinorelbine has shown response rates from 32% to 50% as a first-line treatment and from 15% to 36% as a second-line treatment. (3) (4) (5) (6) (7) Ifosfamide is an alkylating agent that displays single agent activity for treating advanced breast cancer with response rates up to 30%. (8, 9 ) The drug appears to be less myelotoxic and more advantageous for combination chemotherapy with the availability of the uroprotector agent, Mesna.(10) The preclinical results obtained from studies on different cell types (including C3H mammary carcinoma) showed the superiority of ifosfamide over cyclophosphamide. (11, 12) Ifosfamide can be administered at significantly higher doses than cyclophosphamide with considerably much less myelosuppression, and so this permits a higher alkylator dose-intensity for ifosfamide than that for cyclophosphamide. There have been several
Purpose:
The patients with metastatic breast cancer are routinely exposed to taxane and anthracycline as neoadjuvant, adjuvant, and palliative chemotherapeutic agents. This study was designed to evaluate the efficacy and safety of using a vinorelbine and ifosfamide (VI) combination treatment in patients with taxane-resistant metastatic breast cancer. Methods: We evaluated the use of a VI regimen (25 mg/m 2 vinorelbine administered on days 1 and 8 plus 2,000 mg/m 2 ifosfamide administered on day 1-3 every 3 weeks) for breast cancer patients who evidenced tumor progression after palliative taxane treatment. Results: Overall, 35 patients were enrolled in this study: Their median age was 50 years (range, 38-72 years). The overall response rate was 40.0% (14 patients; 95% confidence interval [CI], 23-57%). The median time to progression was 4.5 months (95% CI, 3.5-5.4 months). The median overall survival was 18.3 months (95% CI, 12.9-23.6 months). In the 190 cycle of treatment, the incidence of grade ≥3 neutropenia, anemia, and thrombocytopenia was 29.3%, 4.2%, and 2.0%, respectively. Neutropenic fever was noted in 6 cycles (3.1%). The non-hematological toxicities were not severe: grade 1 or 2 vomiting was observed in 22.8% of the patients. Conclusion: Our results suggest that the use of vinorelbine and ifosfamide (VI) combination chemotherapy appears to be effective and it showed an acceptable toxicity profile in the patients with taxane-resistant metastatic breast cancer.
phase I/II studies that have combined ifosfamide with other agents for treating advanced breast cancer patients, such as doxorubicin, (13) paclitaxel (14) and docetaxel (15, 16) and these studies have demonstrated the feasibility of considerably high ifosfamide doses as well as the substantial activity of the employed combinations.
We have conducted this phase II study to evaluate the efficacy and safety of using vinorelbine and ifosfamide combination chemotherapy in patients with taxane-resistance metastatic breast cancer.
METHODS

Eligibility
To be eligible for this study, the patients were required to have a histologically confirmed diagnosis of carcinoma of the breast, as well as at least one measurable lesion. 
Definition of drug resistance(17)
Primary resistance was defined as progressive disease that occurred during or within 6 months after the completion of treatment in an adjuvant setting, as well as the absence of a documented tumor response in a metastatic setting.
Secondary resistance was defined as disease progression after a documented clinical response during chemotherapy, or disease progression 6 months after the completion of treatment for metastatic disease. A follow-up history taking and physical examinations, tumor measurements and toxicity assessments were conducted prior to each 3-week cycle of therapy. Toxicity was evaluated using the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), Version 3.0.
Treatment protocol
Assessment of response
Patients who had received at least two cycles of therapy were assessable for response; all patients who received treatment were assessable for toxicity. A physical examination, complete blood counts, blood chemistry and chest X-rays were acquired after each cycle of chemotherapy.
Computed tomography scans were repeated every three cycles or earlier for the cases with clinical deterioration.
The responses were assessed by using WHO criteria. 
Statistical methods
This trial was designed to detect a response rate of 30%
as compared to a minimal, clinically meaningful response rate of 10%. The two-stage optimal design proposed by
Simon was adopted, with a statistical power of 80% to accept the hypothesis and 5% significance to reject the Table 2 ). The median follow-up duration was 32.9 months. The median TTP Time to progression (months) 
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OS (Table 3) . Table 2 ).
Dose administration and toxicity
An analysis of side effects demonstrated that the toxi- (Table 4) . In the case of disease progression during the study, salvage chemotherapy was permitted and this was conducted in 26 patients (74.2%) with a variety of drugs.
Trastuzumab was used in 6 of the 10 patients who were positive for a HER2 expression. A total of 20 patients exhibited clinical benefits once more with the salvage chemotherapies, and the median OS might have been prolonged due to that phenomenon.
In this study, the prognostic factors associated with overall survival were the serum hemoglobin level and the sites of dominant metastasis. Lower serum hemoglobin level may induce poorer performance status and decreasing compliance due to the hematologic toxicity itself, which make the patients intolerable to the salvage chemotherapy. (24) Visceral dominant metastasis has been proven to be a poor prognostic factor in the previous studies, (25) and visceral dominant metastasis might be negatively associated with the median OS in this study.
The positive expression of HER2 was not a significant prognostic factor for survival. Six of the 10 patients (60%) with a HER2 overexpression received trastuzumab as salvage chemotherapy, and that might have been associated with survival.
The present combination of vinorelbine and ifosfamide was well-tolerated in metastatic breast cancer patients, even with three or more pretreated chemotherapy regimens. Myelosuppression, mainly neutropenia, was the dose-limiting side effect, and induced dose modifications in this study. Non-hematological toxicities were only grade 1 or 2 vomiting and peripheral neuropathy.
CONCLUSION
Our data indicates that the combination of vinorelbine and ifosfamide appears to be effective and it has an acceptable toxicity profile in taxane-resistant, metastatic breast cancer patients. This combination might be incorporated into the chemotherapy options that are available for the previously heavily-treated breast cancer patients.
